Swiss Pharma Stock News

Sika AG recently reported preliminary 2025 results showing CHF 11.20 billion in sales, modest growth in local currencies but a reported sales decline due to a strong Swiss franc, softer construction demand in markets such as China and the US, and an earnings margin outlook now only slightly above 19% excluding one-off restructuring costs. Management launched the “Fast Forward” cost and investment program, including up to 1,500 job cuts and targeted annual savings of CHF 150–200 million by...

Key Insights Burkhalter Holding's estimated fair value is CHF115 based on 2 Stage Free Cash Flow to Equity With CHF136...

Key Insights Arbonia's significant individual investors ownership suggests that the key decisions are influenced by...

It is hard to get excited after looking at BKW's (VTX:BKW) recent performance, when its stock has declined 4.7% over...

It's not a stretch to say that Komax Holding AG's ( VTX:KOMN ) price-to-sales (or "P/S") ratio of 0.5x right now seems...

Chocoladefabriken Lindt & Sprüngli (SWX:LISN) issued fresh earnings guidance, signaling a planned 20 to 40 basis point annual improvement in operating profit margin from a 16.2% base, beginning with a modest uplift in 2025. See our latest analysis for Chocoladefabriken Lindt & Sprüngli. The updated earnings guidance lands after a mixed year for the shares. The 1 year total shareholder return of 17.58% contrasts with a 90 day share price return decline of 11.76%, suggesting shorter term...

In January 2026, Swiss Federal Railways (SBB) awarded a joint venture between Implenia and Marti five of six lots for the MehrSpur Zurich–Winterthur rail expansion, giving Implenia an approximately CHF 830 million share of a roughly CHF 1.70 billion, decade-long infrastructure program. This long-duration, technically complex tunneling and station-upgrade mandate aligns closely with Implenia’s focus on large infrastructure projects and could reinforce its positioning in higher-value,...

In recent days, Novartis and SciNeuro Pharmaceuticals announced a worldwide licensing and collaboration deal to develop an amyloid beta antibody program for Alzheimer’s disease, while Novartis also unveiled plans for a new radioligand therapy manufacturing facility in Winter Park, Florida, as part of its multi-billion-dollar US investment. Together, these moves highlight how Novartis is pairing early-stage neuroscience innovation with expanded US radioligand production to deepen its...

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

Swisscom AG's ( VTX:SCMN ) price-to-earnings (or "P/E") ratio of 24.3x might make it look like a sell right now...

Tecan Group AG has released unaudited preliminary results for fiscal 2025, reporting second-half sales growth of 0.4% in local currencies but a 5.2% decline in Swiss francs to CHF 443.0 million, with full-year sales down 1.6% in local currencies and 5.5% in Swiss francs to CHF 882.5 million versus 2024. The return to modest second-half growth, despite a full-year sales contraction, highlights a possible turning point in demand momentum amid currency headwinds and lingering operational...

Why the lucerastat data matters for Idorsia shares Idorsia (SWX:IDIA) just put fresh Phase 3 and long term lucerastat data for Fabry disease into the public domain, with kidney and cardiac outcomes now in focus after the study missed its primary pain endpoint. For you as a shareholder or potential investor, this shifts attention to how lucerastat might fit into Idorsia's broader rare disease pipeline, future regulatory discussions, and the perceived value of its R&D portfolio. See our latest...

Earlier in January 2026, Swiss Re AG promoted Christophe Heck to market head Life Health for France, BeNeLux and Switzerland, with Heck now leading the Life Health reinsurance team from Zurich after more than a decade in the industry. This appointment places an experienced leader over several of Swiss Re’s core European Life Health markets, potentially influencing how the group prioritizes growth, risk selection and client engagement across the segment. We’ll now explore how Christophe...

If you have been wondering whether Sika shares are now offering value or still look expensive, this breakdown will help you put the current price into context before you commit fresh capital. Sika shares last closed at CHF149.10, with returns of an 8.7% decline over 7 days, a 6.7% decline over 30 days, an 8.9% decline year to date, and a 30.8% decline over 1 year, adding to a 39.6% decline over 3 years and a 35.0% decline over 5 years. Recent coverage around Sika has focused on its position...

Qantec Automation has announced a new alliance with ABB to deliver open, sustainable smart building and IoT automation solutions across Australia, combining ABB’s building technologies with Qantec’s local market expertise. This collaboration highlights how ABB is using local distribution partnerships to deepen its presence in the smart building segment and support more efficient, lower‑emission infrastructure. We’ll now explore how ABB’s expanded Australian smart building footprint with...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

The Gurit Holding AG ( VTX:GURN ) share price has done very well over the last month, posting an excellent gain of 42...

Key Insights Using the 2 Stage Free Cash Flow to Equity, EMS-CHEMIE HOLDING fair value estimate is CHF601 EMS-CHEMIE...

Key Insights The projected fair value for Bossard Holding is CHF197 based on 2 Stage Free Cash Flow to Equity Current...

If you are trying to work out whether UBS Group at about CHF 37.95 is still offering value or starting to look stretched, you are in the right place. The stock has returned 1.0% over the last 7 days, 10.5% over the last 30 days, 33.4% over the last year and very large gains over 3 and 5 years, while the year to date return sits at a 0.6% decline. Recent attention on UBS Group has been shaped by its integration of Credit Suisse and its evolving role as a major global wealth manager. These...

As European markets show optimism with the STOXX Europe 600 Index rising 2.27% amid a strengthening eurozone economy, investors are increasingly focused on growth companies that insiders are eager to own. In this environment, stocks with high insider ownership can be particularly appealing, as they often indicate confidence from those closest to the company's operations and potential for future success.

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...